shares in this article
ADC Therapeutics SA (NYSE: ADCT) today announced that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin’s lymphoma have been submitted for an oral presentation at the European Hematology Association Hybrid Congress 2022 (EHA2022) were adopted. The congress will take place from 9.-12. June 2022 held virtually and in Vienna (Austria).
“Data from our ongoing pivotal Phase 2 study continue to be extremely encouraging, demonstrating the efficacy and safety of Cami as monotherapy in patients with relapsed or refractory Hodgkin’s lymphoma,” said Joseph Camardo, MD, Chief Medical Officer at ADC Therapeutics. “We are currently advancing Cami towards a potential BLA submission and look forward to sharing this data with the hematology community at EHA2022.
Details of ADC Therapeutics Oral Presentation:
Camidanlumab Tesirine: Updated Efficacy And Safety In An Open-Label, Multicenter, Phase 2 Study Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (R/R CHL)
Date and time of presentation: Friday, June 10, 2022 at 11:45 am 12:00 pm CEST // 5:45 am 6:00 am EDT
Session Title: Hodgkin Lymphoma Clinical
Session room: Hall A8
Abstract No.: S201
Presenter: Carmelo Carlo-Stella, MD, Department of Biomedical Sciences, Humanitas University, and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy
Details of ADC Therapeutics poster presentations:
Health-Related Quality Of Life And Tolerability Of Loncastuximab Tesirine In High-Risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated In A Phase 2 Clinical Trial (LOTIS 2)
Session Date and Time: Friday, June 10, 2022 at 4:30-5:45 p.m. CEST // 10:30-11:45 a.m. EDT
Location: Hall D
Abstract No: P1717
Real-World Characteristics And Clinical Outcomes In Relapse/Refractory Diffuse Large B-Cell Lymphoma Patients Who Received Car-T Therapy
Session Date and Time: Friday, June 10, 2022 at 4:30-5:45 p.m. CEST // 10:30-11:45 a.m. EDT
Location: Hall D
Abstract No.: 1182
Real-World Characteristics And Clinical Outcomes In Relapse/Refractory Diffuse Large B-Cell Lymphoma Post Car-T Failure
Session Date and Time: Friday, June 10, 2022 at 4:30-5:45 p.m. CEST // 10:30-11:45 a.m. EDT
Location: Hall D
Abstract No.: 1181
Titles of ADC Therapeutics abstracts accepted for publication only:
- A Phase 2, Open-Label Study Of Loncastuximab Tesirine In Combination With Rituximab (LONCA-R) In Previously Untreated Unfit/Frail Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9) [Laufende Studien]
- Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
- Phase 3 Randomized Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL (LOTIS-5) [Laufende Studien]
Please note: Times and locations are preliminary and subject to change.
About camidanlumab tesirine (Cami)
Camidanlumab tesirine (Cami) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody that binds to CD25 (HuMax-TAC, licensed from Genmab A/S) and conjugated to the pyrrolobenzodiazepine (PBD) dimer Payload tesirine is conjugated. Once bound to a CD25-expressing tumor cell, Cami is internalized into the cell where enzymes release the PBD-based cytotoxic payload and kill the cell. This applies both to CD25-expressing tumor cells and to CD25-expressing regulatory T cells (Treg). The intratumoral release of the PBD payload can also lead to “bystander killing” of neighboring tumor cells. In addition, PBDs have been shown to induce immunogenic cell death. All of these properties of Cami can enhance immune-mediated antitumor activity.
Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma (HL) and in a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.
About ZYNLONTA (Loncastuximab-Tesirin-Lpyl)
ZYNLONTA is a CD19-targeted antibody-drug conjugate (AWC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell where enzymes release a pyrrolobenzodiazepine (PBD) payload. The highly potent payload binds to the DNA minor groove with little distortion, making it less visible to DNA repair mechanisms. This ultimately stops the cell cycle and the tumor cells die.
The US Food and Drug Administration (FDA) approved ZYNLONTA (loncastuximab-Tesirin-Lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including that not otherwise specified DLBCL, as well as DLBCL arising from low-grade lymphoma and high-grade B-cell lymphoma. The study enrolled a broad spectrum of heavily pretreated patients (median of three prior lines of therapy) with very difficult to treat disease, including patients who were refractory to first-line therapy, patients who were refractory to all prior lines of therapy, and double/triple hit patients -Genetics and patients who received stem cell transplantation and CAR-T therapy prior to their treatment with ZYNLONTA. This indication received accelerated approval from the FDA based on the overall response rate, and further approval for this indication may be subject to verification and characterization of clinical benefit in a confirmatory study.
ZYNLONTA is also being evaluated in combination studies as a treatment option for other B-cell malignancies and in earlier lines of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial biotechnology company improving the quality of life for cancer patients with its next-generation targeted antibody-drug conjugates (ADCs). The Company is advancing the development of its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-targeted AWK ZYNLONTA (Loncastuximab-Tesirin-Lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also being developed in combination with other active ingredients. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 clinical trial in relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial in various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has several ADCs in ongoing clinical and pre-clinical development.
ADC Therapeutics is based in Lausanne (Biople), Switzerland, with offices in London, the San Francisco Bay Area and New Jersey. Visit https://adctherapeutics.com/ for more information. You can also follow the company on Twitter and LinkedIn.
CYNLONTA is a registered trademark of ADC Therapeutics SA.
The source language in which the original text is published is the official and authorized version. Translations are included for better understanding. Only the language version that was originally published is valid. Therefore, compare translations with the original language version of the publication.
View original version on businesswire.com: https://www.businesswire.com/news/home/20220512005636/en/
Leverage must be between 2 and 20
No data